Article
Oncology
Nidal Muhanna, Donovan Eu, Harley H. L. Chan, Catriona Douglas, Jason L. Townson, Marco A. Di Grappa, Reza M. Mohamadi, Shana O. Kelley, Scott Bratman, Jonathan C. Irish
Summary: This study investigated the kinetics of ctDNA and CTCs following radiation therapy in a preclinical head and neck model. The results showed that ctDNA can reflect overall tumor burden, while CTC detection is related to tumor size. Although ctDNA levels decrease over the course of treatment, there may be increases seen particularly upon initiation of radiation and during scheduled treatment breaks.
Review
Oncology
Natalia Birknerova, Veronika Mancikova, Evan David Paul, Jan Matyasovsky, Pavol Cekan, Vladimir Palicka, Helena Parova
Summary: Liquid biopsy is a promising alternative to tissue biopsies, offering real-time detection and monitoring of tumor properties. It has significant implications for the diagnosis and prognosis of advanced stage head and neck cancer patients.
Editorial Material
Oncology
Shrikant B. Mali
Summary: Liquid biopsy is a valuable tool in personalized medicine, providing real-time monitoring of cancer progression and patient follow-up. This minimally invasive procedure analyzes circulating tumor cells (CTCs) and various circulating tumor-derived materials, such as ctDNA, miRNAs, and EVs. CTC analysis has significant implications for prognosis, minimal residual disease (MRD) detection, treatment selection, and cancer patient monitoring.
Article
Oncology
Kirsty Taylor, Jinfeng Zou, Marcos Magalhaes, Marc Oliva, Anna Spreafico, Aaron R. Hansen, Simon S. McDade, Vicky M. Coyle, Mark Lawler, Elena Elimova, Scott V. Bratman, Lillian L. Siu
Summary: Immune checkpoint blockade is an important treatment for recurrent/metastatic head and neck squamous cell cancer, but only a subset of patients benefit from it. Monitoring plasma circulating tumor DNA (ctDNA) levels and changes during treatment can help assess disease burden and predict patient outcomes. This study showed that early changes in ctDNA after one cycle of treatment can predict progression-free survival and overall survival in patients with recurrent/metastatic head and neck squamous cell cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Editorial Material
Biotechnology & Applied Microbiology
Peiyong Jiang, Y. M. Dennis Lo
Summary: A new assay for cell-free DNA fragmentation enhances the prediction of gene expression in liquid biopsies.
NATURE BIOTECHNOLOGY
(2022)
Article
Dentistry, Oral Surgery & Medicine
Oscar Rapado-Gonzalez, Ana Maria Rodriguez-Ces, Rafael Lopez-Lopez, Maria Mercedes Suarez-Cunqueiro
Summary: In the era of precision medicine, liquid biopsies based on cell-free DNA have emerged as a promising tool in oncology. Numerous studies have reported on the potential of cfDNA analysis as diagnostic, prognostic, and monitoring biomarkers for head and neck cancer. ctDNA analysis can detect cancer-specific genetic and epigenetic alterations.
JAPANESE DENTAL SCIENCE REVIEW
(2023)
Review
Medicine, General & Internal
Mayur D. Mody, James W. Rocco, Sue S. Yom, Robert Haddad, Nabil F. Saba
Summary: Head and neck cancer is the seventh most common type of cancer worldwide, with the predominant risk factors being tobacco use, alcohol abuse, and oncogenic viruses. Treatment typically involves a multidisciplinary approach with surgery, radiotherapy, and systemic therapy, and is challenging due to site-specific and histology-specific variations.
Article
Oncology
Wei Liu, Tong Ji, Chenping Zhang, Qin Zhou, Zhexuan Bao
Summary: Cell-free DNA (cfDNA) hypermethylation in blood-based liquid biopsy is a promising minimally invasive biomarker for the diagnosis and risk assessment of head and neck cancer (HNC). However, more research and discussion on this issue is still needed.
Article
Medical Laboratory Technology
Dimo Dietrich, Simone Weider, Luka de Vos, Timo Jakob Vogt, Moritz Faerber, Romina Zarbl, Alina Hunecke, Ann-Kathrin Glosch, Jennis Gabrielpillai, Friedrich Bootz, Franz-Georg Bauernfeind, Franz-Josef Kramer, Glen Kristiansen, Peter Brossart, Sebastian Strieth, Alina Franzen
Summary: This study aimed to evaluate the clinical performance of SEPT9 ccfDNA methylation in detecting post-surgical minimal residual disease in localized or locally advanced HNSCC patients. The results showed that post-surgical SEPT9 ccfDNA methylation positivity was associated with tumor site, tumor stage, nodal category, extracapsular extension, lymphatic and vascular invasion, and surgical margin. It was proven to be an independent prognostic factor.
CLINICAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Marilina Mascaro, Exequiel G. Alonso, Karen Schweitzer, Martin E. Rabassa, Jessica A. Carballido, Agustina Ibarra, Eliana N. Alonso, Vicente Bermudez, Lucia Fernandez Chavez, Georgina P. Colo, Maria Julia Ferronato, Pamela Pichel, Sergio Recio, Valentina Clemente, Maria Eugenia Fermento, Maria Marta Facchinetti, Alejandro C. Curino
Summary: This study elucidates the mechanisms of HO-1 in HNSCC, showing that high expression of HO-1 is associated with decreased patient survival. HO-1 promotes cell cycle progression and cell viability. HO-1's protumor activities depend, at least in part, on its nuclear localization.
Article
Health Care Sciences & Services
Lana Sayal, Omar Hamadah, Aroub AlMasri, Majdy Idrees, Issam Kassem, Wafa Habbal, Buthainah Alsalamah, Omar Kujan
Summary: Changes in the copy numbers of cell-free nuclear DNA (cf-nDNA) and cell-free mitochondrial DNA (cf-mtDNA) have diagnostic potential in head and neck squamous cell carcinoma (HNSCC). This study examined the use of saliva-based cf-nDNA and cf-mtDNA to predict overall survival in HNSCC patients. Higher copy numbers of cf-nDNA and cf-mtDNA were associated with deceased patients and poorer overall survival. Multivariate analysis showed that the copy numbers of cf-nDNA and cf-mtDNA, along with HNSCC stage, were predictors of overall survival. Saliva can be a reliable and non-invasive source to predict HNSCC patient survival, with cf-mtDNA levels acting as the sole predictor.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
Anela Tosevska, Marco Morselli, Saroj K. Basak, Luis Avila, Parag Mehta, Marilene B. Wang, Eri S. Srivatsan, Matteo Pellegrini
Summary: Liquid biopsies are becoming more important in the diagnosis and monitoring of cancer. A botanical drug combination called APG-157 is emerging as a new class of cancer therapeutics, targeting multiple pathways and providing a durable clinical response, wide therapeutic window, and high safety level. A methodology that uses circulating plasma cell-free RNA (cfRNA) as a sensitive indicator of patient response to drug treatment has been developed. This study provides proof of principle for the utility of cfRNAs as non-invasive circulating biomarkers for monitoring the efficacy of APG-157 in head and neck cancer.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
M. Cisneros-Villanueva, L. Hidalgo-Perez, M. Rios-Romero, A. Cedro-Tanda, C. A. Ruiz-Villavicencio, K. Page, R. Hastings, D. Fernandez-Garcia, R. Allsopp, M. A. Fonseca-Montano, S. Jimenez-Morales, V Padilla-Palma, J. A. Shaw, A. Hidalgo-Miranda
Summary: Cell-free DNA analysis is a promising method for the diagnosis and treatment selection of cancer patients. Despite the need for standardization and technical validation, numerous clinical trials have shown its potential in early cancer detection and treatment improvement.
BRITISH JOURNAL OF CANCER
(2022)
Review
Cell Biology
Xiaomin Huang, Pascal H. G. Duijf, Sharath Sriram, Ganganath Perera, Sarju Vasani, Lizbeth Kenny, Paul Leo, Chamindie Punyadeera
Summary: Head and Neck cancers (HNC) are a diverse group of upper aero-digestive tract cancer with a high mortality rate. Existing methods for diagnosing and treating HNC mainly rely on cytopathology or histopathology of tumour tissue. However, liquid biopsy, specifically circulating tumour DNA (ctDNA), is emerging as a promising alternative to overcome the challenges of tumour heterogeneity and limited access to tumour tissue. This review focuses on the mechanisms, technological advances, and clinical applications of ctDNA in HNC.
JOURNAL OF BIOMEDICAL SCIENCE
(2023)
Article
Oncology
Giulia Siravegna, Connor J. O'Boyle, Shohreh Varmeh, Natalia Queenan, Alexa Michel, Jarrod Stein, Julia Thierauf, Peter M. Sadow, William C. Faquin, Simon K. Perry, Adam Z. Bard, Wei Wang, Daniel G. Deschler, Kevin S. Emerick, Mark A. Varvares, Jong C. Park, John R. Clark, Annie W. Chan, Vanessa Carlota Andreu Arasa, Osamu Sakai, Jochen Lennerz, Ryan B. Corcoran, Lori J. Wirth, Derrick T. Lin, A. John Iafrate, Jeremy D. Richmon, Daniel L. Faden
Summary: This study demonstrates that a noninvasive diagnostic approach for HPV+HNSCC has improved accuracy, reduced cost, and a shorter time to diagnosis compared with standard clinical workup, making it a viable alternative in the future.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Ali Hosni, Shao Hui Huang, Kevin Chiu, Wei Xu, Jie Su, Andrew Bayley, Scott V. Bratman, John Cho, Meredith Giuliani, John Kim, Brian O'Sullivan, Jolie Ringash, John Waldron, Anna Spreafico, Eugene Yu, John R. de Almeida, Eric Monteiro, Douglas B. Chepeha, Jonathan C. Irish, David P. Goldstein, Andrew Hope
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Article
Oncology
Lachlan J. McDowell, Jolie Ringash, Wei Xu, Biu Chan, Lin Lu, John Waldron, Kathy Rock, Nathaniel So, Shao Hui Huang, Meredith Giuliani, Andrew Hope, Brian O'Sullivan, Scott V. Bratman, John Cho, John Kim, Raymond Jang, Andrew Bayley, Lori J. Bernstein
RADIOTHERAPY AND ONCOLOGY
(2019)
Article
Hematology
Jessica L. Brady, Michael S. Binkley, Carla Hajj, Monica Chelius, Karen Chau, Alex Balogh, Mario Levis, Andrea Riccardo Filippi, Michael Jones, Michael Mac Manus, Andrew Wirth, Masahiko Oguchi, Anders Krog Vistisen, Therese Youssef Andraos, Andrea K. Ng, Berthe M. P. Aleman, Seo Hee Choi, Youlia Kirova, Sara Hardy, Gabriele Reinartz, Hans T. Eich, Scott V. Bratman, Louis S. Constine, Chang-Ok Suh, Bouthaina Dabaja, Tarec C. El-Galaly, David C. Hodgson, Umberto Ricardi, Joachim Yahalom, Richard T. Hoppe, George Mikhaeel
Review
Oncology
Jianjun Ren, Wen Yang, Jie Su, Xue Ren, Rouhi Fazelzad, Tiong Albert, Steven Habbous, David P. Goldstein, John R. de Almeida, Aaron Hansen, Raymond Jang, Scott Bratman, Andrew Hope, Ruiqi Chen, Jing Wang, Yang Xu, Danni Cheng, Yu Zhao, Wei Xu, Geoffrey Liu
INTERNATIONAL JOURNAL OF CANCER
(2019)
Article
Oncology
Michael S. Binkley, Jessica L. Brady, Carla Hajj, Monica Chelius, Karen Chau, Alex Balogh, Mario Levis, Andrea Riccardo Filippi, Michael Jones, Sameera Ahmed, Michael MacManus, Andrew Wirth, Masahiko Oguchi, Anders Krog Vistisen, Therese Youssef Andraos, Andrea K. Ng, Berthe M. P. Aleman, Seo Hee Choi, Youlia M. Kirova, Sara Hardy, Gabriele Reinartz, Hans T. Eich, Scott Bratman, Louis S. Constine, Chang-Ok Suh, Bouthaina Dabaja, Tarec C. El-Galaly, David C. Hodgson, Umberto Ricardi, Joachim Yahalom, N. George Mikhaeel, Richard T. Hoppe
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Article
Oncology
Astrid Billfalk-Kelly, Eugene Yu, Jie Su, Brian O'Sullivan, John Waldron, Jolie Ringash, Eric Bartlett, Bayardo Perez-Ordonez, Ilan Weinreb, Andrew Bayley, Scott Bratman, John Cho, Meredith Giuliani, Andrew Hope, Ali Hosni, John Kim, Aaron R. Hansen, John de Almeida, Li Tong, Wei Xu, Shao Hui Huang
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Meeting Abstract
Oncology
Marco Adelmo James Iafolla, Cindy Yang, Scott Dashner, Wei Xu, Aaron Richard Hansen, Philippe L. Bedard, Stephanie Lheureux, Anna Spreafico, Albiruni Ryan Abdul Razak, Hsin-Ta Wu, Svetlana Shchegrova, Zhihui (Amy) Liu, Pamela S. Ohashi, Dax Torti, Maggie C. Louie, Himanshu Sethi, Alexey Aleshin, Lillian L. Siu, Scott Victor Bratman, Trevor John Pugh
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Biochemistry & Molecular Biology
Ting Ting Wang, Sagi Abelson, Jinfeng Zou, Tiantian Li, Zhen Zhao, John E. Dick, Liran I. Shlush, Trevor J. Pugh, Scott V. Bratman
NUCLEIC ACIDS RESEARCH
(2019)
Meeting Abstract
Oncology
S. Sanduleanu, A. Jochems, T. Upadhaya, A. Even, R. Leijenaar, F. Dankers, R. Klaassen, H. Woodruff, M. Hatt, H. Kaanders, O. Hamming-Vrieze, H. Van Laarhoven, R. Subramiam, S. Huang, B. O'Sullivan, S. Bratman, L. Dubois, R. Miclea, D. Di Perri, X. Geets, D. De Ruysscher, F. Hoebers, P. Lambin
RADIOTHERAPY AND ONCOLOGY
(2019)
Meeting Abstract
Oncology
S. Bratman
RADIOTHERAPY AND ONCOLOGY
(2019)
Editorial Material
Genetics & Heredity
Daniel V. Araujo, Scott V. Bratman, Lillian L. Siu
Article
Oncology
Reza Reiazi, Colin Arrowsmith, Mattea Welch, Farnoosh Abbas-Aghababazadeh, Christopher Eeles, Tony Tadic, Andrew J. Hope, Scott V. Bratman, Benjamin Haibe-Kains
Summary: Recent studies have shown promising results in exploring the application of radiomics features in medicine, but their robustness is affected by variation in imaging parameters, which in turn may impact the prediction performance of machine learning models. There is a need for further evaluation on how the robustness of radiomic features affects predictions, especially in clinical oncology for HPV association prediction.
Article
Endocrinology & Metabolism
Xiao Zhao, Pamela Psarianos, Laleh Soltan Ghoraie, Kenneth Yip, David Goldstein, Ralph Gilbert, Ian Witterick, Hilary Pang, Ali Hussain, Ju Hee Lee, Justin Williams, Scott V. Bratman, Laurie Ailles, Benjamin Haibe-Kains, Fei-Fei Liu
Meeting Abstract
Oncology
K. J. Jerzak, D. W. Cescon, S. K. Chia, S. Bratman, M. Ennis, V. Stambolic, M. Chang, R. Dowling, P. J. Goodwin
Article
Oncology
Sangjune Laurence Lee, Michael Cabanero, Martin Hyrcza, Marcus Butler, Fei-Fei Liu, Aaron Hansen, Shao Hui Huang, Ming-Sound Tsao, Yuyao Song, Lin Lu, Wei Xu, Douglas B. Chepeha, David P. Goldstein, Ilan Weinreb, Scott Bratman
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2019)